Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	INCAGN02385 + INCAGN02390 + Retifanlimab
Synonyms
Therapy Description

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 3 of 3 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
INCAGN02385		INCAGN 02385\|INCAGN-02385\|tuparstobart	LAG3 Antibody 19	INCAGN02385 is a antibody that targets LAG-3, potentially resulting in increased T-cell response (AACR Annual Meeting 2018, Abstract 3919).
INCAGN02390		INCAGN 02390\|INCAGN-02390	TIM-3 Antibody 9	INCAGN02390 is an antibody that targets the immune inhibitory receptor TIM-3, potentially resulting in decreased tumor growth when combined with other immune checkpoint inhibitors (Cancer Res July 1 2018 (78) (13 Supplement) 3825).
Retifanlimab	Zynyz	MGA 012\|INCMGA00012\|MGA012\|retifanlimab-dlwr	Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 131	Zynyz (retifanlimab) is a humanized IgG4 monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT085). Zynyz (retifanlimab) is FDA approved for use in adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma, and in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) or as a single agent for patients with anal canal squamous cell carcinoma (FDA.gov).

Showing 1 to 3 of 3 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 0 to 0 of 0 entries

Showing 0 to 0 of 0 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 4 of 4 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT04370704	Phase Ib/II	INCAGN02385 + INCAGN02390 + Retifanlimab INCAGN02385 + INCAGN02390	Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies	Active, not recruiting	USA \| AUS	0
NCT05287113	Phase II	INCAGN02385 + Retifanlimab Retifanlimab INCAGN02385 + INCAGN02390 + Retifanlimab	Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS >= 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Active, not recruiting	USA \| POL \| NLD \| ITA \| GRC \| FRA \| ESP \| DEU \| CAN \| BEL	4
NCT06056895	Phase II	INCAGN02385 + INCAGN02390 + Retifanlimab	Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma (TRICK-MCC)	Active, not recruiting	USA	0
NCT06290622	Phase I	INCAGN02385 + INCAGN02390 + Retifanlimab	PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL	Withdrawn		0

Showing 1 to 4 of 4 entries

Filter rows:

Additional content available in CKB BOOST